Results 61 to 70 of about 3,281 (174)

Real‐world evidence on the safety and effectiveness of thrombopoietin receptor agonists in aplastic anaemia: A descriptive study using Japanese hospital administrative data

British Journal of Haematology, EarlyView.
Kayoko Mizuno, Yutaka Shimazu, Toshiki Fukasawa, Satoru Ito, Yukihiro Nishio, Mami Shimizu, Koji Kawakami   +6 more
wiley   +1 more source

Severe Thrombocytopenia Associated With Glucagon‐Like‐1 Receptor Agonists (GPL‐1RA): A SONAR Report

Diabetes, Obesity and Metabolism, EarlyView.
Charles L. Bennett, Chadi Nabhan, Demir Uslu, Yogitha Dadi, David Aboulafia, Barbara Senger, Joseph Magagnoli, Kelvin Rojas, Gurdeep Singh, Linda Martin, Edward Smith, Samuel Ruder, Chien‐Hsiang Weng, Nikhil Uppal, Mia Lynch, James B. Bussel   +15 more
wiley   +1 more source

Pharmacoeconomic Analysis of the Use of Thrombopoietin Receptors Agonists in Idiopathic Thrombocytopenic Purpura Therapy

Клиническая онкогематология, 2017
Background. New medications, thrombopoietin mimetics which were recently introduced into clinical practice allowed to achieve clinical response in patients with chronic glucocorticoid-resistant idiopathic thrombocytopenic purpura (ITP). However, the high
Vasilii Anatol’evich Shuvaev, S. V. Voloshin, A. K. Hadzhidis, A. V. Chechetkin   +3 more
doaj   +1 more source

Cognitive Impairment, Depression and Cerebral Microbleeds in Immune Thrombocytopenia (ITP)

American Journal of Hematology, Volume 101, Issue 11, Page 2934-2938, November 2026.
Camelia Vladescu, Rozanna Meijboom, Alice C. J. Hart, Deena Paul, Christine Ademokun, Ariam Teklemichael, Bridget Chivers, Anastasia Gontsarova, Richard Szydlo, Adam D. Waldman, Nichola Cooper   +10 more
wiley   +1 more source

Efficacy and Safety of rhIL‐11 in the Treatment of Cancer Therapy‐Induced Thrombocytopenia: A Multicenter Retrospective Study

Cancer Medicine, Volume 15, Issue 7, July 2026.
ABSTRACT Objective This real‐world study aimed to investigate the cancer therapy‐induced thrombocytopenia (CTIT) profile and evaluate the efficacy and safety of recombinant human interleukin‐11 (rhIL‐11) in its management. Methods Retrospective analysis included 12,431 CTIT patients treated with rhIL‐11 across 58 Chinese centers (July 2023–June 2024 ...
Yingmei Wen, Yi Dong, Yingge Li, Jinxiong Xia, Zheming Liu, Yuanyuan Wang, Ruibin Li, Ming Wang, Bin Xu, Dongling Tang, Lulu Chen, Huibo Zhang, Qibin Song, Yi Yao   +13 more
wiley   +1 more source

Use of romiplostim in pregnancy for refractory idiopathic thrombocytopenic purpura: Two case reports with maternal and fetal outcomes and literature review

, 2018
Idiopathic thrombocytopenic purpura is a relatively rare complication occurring in pregnancy, with the potential for serious maternal and fetal outcomes.
John Svigos, David M Ross, Simon Kane, Mark R Morton, Su J Chua   +4 more
core   +1 more source

Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports

, 2018
Romiplostim is a thrombopoietin receptor agonist approved for the treatment of immune thrombocytopenia purpura. When following FDA-approved romiplostim prescribing recommendations to withhold treatment for platelet counts above 400k/µL, some patients ...
Charles J Parker, George M Rodgers, Jeffrey A Gilreath, Shilpa Paul, Mei Wei, David D Stenehjem   +5 more
core   +1 more source

Efficacy and safety of romiplostim in adult Iraqi patients with refractory immune thrombocytopenia

Iraqi Journal of Hematology, 2020
BACKGROUND: Immune thrombocytopenia (ITP) is an immune-mediated acquired disease characterized by decrease of the platelet count. The majority of adult patients progress to chronic stage with some of them failed to respond or relapsed after the second ...
Ali Khazaal Jumaa, Tareq Abdullah Saleh, Asaad Abdulameer Khalaf, Mohammed Saleem Abbas   +3 more
doaj   +1 more source

Real‐World Safety and Efficacy of Avatrombopag in Adults with Immune Thrombocytopenia: A Systematic Review and Meta‐Analysis

European Journal of Haematology, Volume 117, Issue 1, Page 174-185, July 2026.
ABSTRACT Objective This systematic review and meta‐analysis aimed to evaluate the risk of thromboembolic events and assess the overall safety and effectiveness of avatrombopag in adult patients with immune thrombocytopenia using real‐world evidence. Methods A systematic search was conducted following the PRISMA 2020 guidelines.
M. L. Lozano, D. Valcarcel
wiley   +1 more source

Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain

Case Reports in Hematology, 2017
Romiplostim, a thrombopoietin-receptor agonist (TPO-ra), is a highly effective option in primary immune thrombocytopenia (ITP), with 80–90% of patients achieving platelet responses after few weeks of treatment.
María-Eva Mingot-Castellano, Carlos Grande-García, David Valcárcel-Ferreiras, Clara Conill-Cortés, Loreto de Olivar-Oliver   +4 more
doaj   +1 more source